111 completed, 40 unknown, 31 terminated, 24 recruiting. 231 Phase 2, 45 Phase 1, 29 Phase 3.
Follow Liver Cirrhosis: new trials by email Literature Review of Liver Cirrhosis trials Research Report on Liver Cirrhosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Erlotinib for Hepatocellular Carcinoma Chemoprevention erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-12-01 | 2026-06-24 |
| Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni | Phase 2 / Phase 3 | Not yet recruiting | Rhode Island Hospital | 600 | 2026-11-01 | 2026-08-12 |
| Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease | Phase 2 | Not yet recruiting | Mayo Clinic | 15 | 2026-11-01 | 2026-09-28 |
| A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia Foscenvivint - Liver Cirrhosis | Phase 2 | Recruiting | Kiminori Kimura, MD | 7 | 2026-10-01 | 2026-10-05 |
| Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis Seladelpar, PTM Seladelpar, Cilofexor Dose B - Primary Biliary Cholangitis | Phase 2 | Recruiting | Gilead Sciences | 132 | 2026-10-01 | 2026-10-27 |
| Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis Standard background therapy, Placebo, hUC-MSC Dose Level 1 - Primary Biliary Cholangitis | Phase 1 / Phase 2 | Not yet recruiting | Beijing 302 Hospital | 68 | 2026-08-31 | 2026-08-31 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 150 | 2026-07-06 | 2026-10-26 |
| A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis | Phase 2 | Recruiting | Yaqrit Ltd | 78 | 2026-06-29 | 2026-09-21 |
| TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis Nalmefene, Placebo - Pruritus, Primary Biliary Cholangitis | Phase 2 | Not yet recruiting | Tharimmune Inc | 40 | 2026-06-01 | 2025-09-09 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Not yet recruiting | RenJi Hospital | 44 | 2026-06-01 | 2026-07-01 |
| Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis AZD2389, Placebo - Liver Fibrosis, Hepatic Cirrhosis | Phase 2 | Recruiting | AstraZeneca | 104 | 2026-05-07 | 2026-10-19 |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) BI 3802876, Placebo - Liver Cirrhosis | Phase 2 | Recruiting | Boehringer Ingelheim | 30 | 2026-02-27 | 2026-10-14 |
| TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol - HCC, Liver Cirrhosis | Phase 2 | Not yet recruiting | Tongji Hospital | 78 | 2025-12-31 | 2026-01-20 |
| Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy Entecavir (ETV), Zinc (zinc sulphate) - Liver Fibroses, HBV (Hepatitis B Virus) | Phase 2 | Not yet recruiting | Tanta University | 44 | 2025-09-01 | 2025-08-28 |
| Digoxin In NASH (CODIN) Digoxin, Placebo - NASH, NAFLD | Phase 2 | Recruiting | Yale University | 144 | 2025-06-05 | 2026-05-26 |
| CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver - Liver Diseases, Liver Cancer | Phase 1 / Phase 2 | Recruiting | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | 90 | 2025-06-01 | 2025-07-08 |
| Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis Dabigatran, Enoxaparin - Portal Vein Thrombosis, Liver Cirrhosis | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 120 | 2025-01-31 | 2025-02-10 |
| A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. AZD2389 - Liver Fibrosis, Hepatic Cirrhosis | Phase 2 | Completed | AstraZeneca | 40 | 2024-12-06 | 2026-07-06 |
| Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis Tremelimumab, Durvalumab - Hepatocellular Carcinoma, Cirrhosis, Liver | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 32 | 2024-12-02 | 2026-01-06 |
Showing 20 of 231. Sign in to see all of them.
Liver Cirrhosis, Biliary (63) · Fibrosis (31) · Non-alcoholic Fatty Liver Disease (27) · Hypertension, Portal (15) · Hepatitis C (13) · Ascites (12) · Liver Diseases (12) · Carcinoma, Hepatocellular (9) · Fatty Liver (9) · Hepatic Encephalopathy (9) · Pruritus (9) · Liver Cirrhosis, Alcoholic (8) · End Stage Liver Disease (6) · Liver Neoplasms (6)
Pathologic Processes (231) · Pathological Conditions, Signs and Symptoms (231) · Digestive System Diseases (227) · Liver Diseases (219) · Fibrosis (200) · Bile Duct Diseases (63) · Biliary Tract Diseases (62) · Cholestasis, Intrahepatic (62) · Cholestasis (60) · Hepatitis (23) · Fatty Liver (21) · Infections (21) · Blood-Borne Infections (19) · Communicable Diseases (19)
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (6) · Ursodeoxycholic Acid (6) · Fenofibrate (5) · obeticholic acid (5) · simtuzumab (5) · Ribavirin (4) · Rifaximin (4) · Albumins (3) · Danazol (3) · ICG 001 (3) · Probiotics (3) · satavaptan (3) · (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (2) · 3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid (2) · Bezafibrate (2)
Gilead Sciences (9) · AstraZeneca (6) · Beijing 302 Hospital (5) · Conatus Pharmaceuticals Inc. (5) · Intercept Pharmaceuticals (5) · Air Force Military Medical University, China (4) · Sun Yat-sen University (4) · Boehringer Ingelheim (3) · Bristol-Myers Squibb (3) · GlaxoSmithKline (3) · Kiminori Kimura, MD (3) · Mirum Pharmaceuticals, Inc. (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Post Graduate Institute of Medical Education and Research, Chandigarh (3) · Sanofi (3)
United States (102) · United Kingdom (40) · China (38) · Spain (38) · Canada (34) · Germany (33) · France (26) · Italy (25) · Belgium (18) · Australia (16) · Japan (14) · South Korea (12) · India (11) · Netherlands (10) · Puerto Rico (10)
Daiming Fan (3) · Kiminori Kimura, MD (3) · Cynthia Levy, MD (2) · David Hagerty, MD (2) · Eric Bellissant, MD, PhD (2) · Liem Nguyen (2) · Stephen Harrison, MD (2) · Stephen J Rossi, PharmD (2) · Virendra Singh, DM (2)
PMID 25543678, PMID 29990488, PMID 33307033, PMID 33657443, PMID 36750244, PMID 38780109, PMID 40439725, PMID 10102814, PMID 15740535, PMID 16552809, PMID 16966752, PMID 17903050, PMID 18068515, PMID 18508290, PMID 20541828, PMID 20953964, PMID 21083674, PMID 21233083, PMID 21810549, PMID 23220074, PMID 23664631, PMID 23782511, PMID 24074360, PMID 24561556, PMID 24835895, PMID 24876849, PMID 25329189, PMID 25500425, PMID 25623044, PMID 25954497, PMID 26006200, PMID 26972567, PMID 27192671, PMID 27232579, PMID 27431238, PMID 27554134, PMID 28187915, PMID 28245467, PMID 28480218, PMID 28818518, PMID 29274193, PMID 29486918, PMID 29790196, PMID 29859173, PMID 29913280, PMID 30153359, PMID 30180806, PMID 30193962, PMID 31731005, PMID 31812510
2016 (5), 2023 (4), 2019 (3), 2005 (2), 2014 (2), 2015 (2), 2009 (1), 2017 (1), 2018 (1), I01CX002436 (1), P20CA252732 (1), P30CA124435 (1), P30DK034989 (1), P50CA295495 (1), R01AI184979 (1)